Where Is the Trust Boundary for AI Agents in Manufacturing: Lessons from Aviation, Medicine, and Finance
Cross-industry analysis of AI autonomy governance — how aviation, healthcare, and finance define trust boundaries, and what manufacturing should adopt.
Serhiy Andrejev
Lead Machine Learning Developer
Every industry that has entrusted consequential decisions to automated systems has had to answer the same fundamental question: how much autonomy is too much? Aviation, medicine, and finance each spent decades defining their trust boundaries — through regulation, catastrophic failures, and iterative refinement. Manufacturing is now facing this question with AI agents, and it would be imprudent to learn only from its own mistakes when three mature precedents already exist.
Introduction
The discussion around AI agents in manufacturing often gravitates toward capability: what the system can do, how fast it processes data, how accurately it predicts failures. In our practice of deploying AI across industrial enterprises in Ukraine and the EU, we observe that this framing misses the essential question. The question is not what an AI agent can do — it is what an AI agent should be allowed to do, under what conditions, and with what safeguards.
This is not a technical question. It is a managerial and organizational one. A language model connected to a SCADA system can, in principle, adjust process parameters autonomously. Whether it should is a decision that involves safety engineering, regulatory compliance, liability allocation, and organizational culture. The technology is often ready before the institution is.
According to McKinsey's 2025 survey of over 100 COOs at major manufacturers, 93% plan to increase AI spending, yet two-thirds report that implementation remains at the exploration or targeted-implementation stage, with only 2% having fully embedded AI across operations [1]. The gap between investment intent and deployment maturity suggests that the limiting factor is not budget or technology — it is trust, governance, and the absence of clear frameworks for AI autonomy.
Other industries have navigated this exact transition. Aviation has spent over four decades refining the boundary between pilot authority and autopilot control. Medicine has developed a rigorous regulatory apparatus for AI-assisted diagnostics. Finance has built circuit breakers and oversight mechanisms after learning that unchecked algorithmic autonomy can destabilize markets. Each domain offers transferable lessons that manufacturing should not ignore.
The Aviation Lesson: Graduated Autonomy and Proven Track Records
Aviation provides perhaps the most structured model for managing automated decision-making. The SAE J3016 standard, originally developed for automotive applications, defines six levels of driving automation from Level 0 (no automation) to Level 5 (full automation under all conditions) [2]. While designed for road vehicles, the graduated autonomy model reflects a principle that aviation established decades earlier.
Modern commercial aircraft operate with highly capable autopilot systems that manage altitude, speed, navigation, and even landing under certain conditions. Yet the aviation industry's approach to autonomy is defined not by what the technology can do, but by a carefully layered trust architecture:
Certification before deployment. No autopilot function enters service without exhaustive certification by authorities such as the FAA and EASA. The certification process evaluates not only normal operation but also degraded modes, edge cases, and failure scenarios. The equivalent in manufacturing AI would be systematic validation of agent behavior under abnormal production conditions — equipment faults, sensor failures, out-of-specification materials — not just nominal operation.
Fallback mechanisms as first-class requirements. Aviation systems are designed with the assumption that automation will fail. Every autopilot function has a defined reversion path to manual control. The pilot can always override. This is not a contingency plan — it is a core design principle. In manufacturing, this translates to ensuring that every AI agent action is reversible and that human operators can assume control at any point without system degradation.
Proven track record as a trust currency. Trust in aviation automation was not granted — it was earned over millions of flight hours. New autopilot capabilities are introduced incrementally, with extensive operational data collection before the next level of autonomy is enabled. The industry does not leap from manual to autonomous; it progresses through supervised automation, bounded autonomy, and only then — after extensive evidence of reliability — grants broader authority to the system.
The critical insight from aviation is that autonomy is not a binary state but a spectrum, and progression along that spectrum requires demonstrable evidence at each level. An AI agent in manufacturing should earn its autonomy the same way an autopilot does — through accumulated operational evidence, not through a vendor's capability demonstration.
The Medical AI Lesson: Second Opinion, Not Primary Judgment
Healthcare has developed a fundamentally different model for AI trust — one where the system's role is explicitly defined as advisory, not authoritative. The FDA's approach to AI/ML-based software as a medical device (SaMD) illustrates this clearly.
In January 2025, the FDA issued comprehensive draft guidance on "Artificial Intelligence-Enabled Device Software Functions," representing the first lifecycle-oriented framework for AI-enabled medical devices [3]. The guidance addresses a critical shift: from treating AI as a static product to managing it as a continuously evolving system. Key principles include:
AI as a second opinion. The predominant deployment model for medical AI is "computer-aided detection" or "computer-aided diagnosis" — the AI highlights potential findings, but the clinician makes the diagnostic decision. The system's output is one input among many, not the final judgment. In manufacturing terms, this is analogous to an AI agent that flags anomalies and suggests root causes but does not autonomously initiate corrective action on critical processes.
Human-AI team performance. The FDA's 2025-2026 guidance introduces the concept of "Human-AI Team" validation, moving beyond traditional usability testing to assess whether users correctly interpret AI outputs, understand model limitations, and recognize uncertainty [3]. This is directly relevant to manufacturing: an operator who trusts an AI agent's recommendation without understanding its confidence level or data basis is a systemic risk, regardless of the model's accuracy.
Predetermined change control. The FDA requires manufacturers to submit predetermined change control plans that define, in advance, what modifications an AI system may make to itself and under what conditions [3]. This addresses the fundamental challenge of AI systems that learn and adapt post-deployment — a challenge equally present in manufacturing AI agents that update their models based on new production data.
Liability architecture. In healthcare, liability for AI-assisted decisions follows established frameworks: the clinician remains ultimately responsible, the device manufacturer bears product liability, and the institution bears systemic oversight responsibility. This tripartite structure has no established equivalent in manufacturing AI, which creates significant uncertainty. When an AI agent adjusts a process parameter that leads to a quality defect, who bears responsibility — the operator who accepted the recommendation, the integrator who configured the agent, or the enterprise that authorized its deployment?
The medical model demonstrates that even highly accurate AI systems — FDA has authorized over 1,000 AI-enabled devices — can be deployed effectively within a framework that explicitly limits their authority while maximizing their informational value.
The Finance Lesson: Circuit Breakers and Systemic Risk
The financial industry offers a cautionary tale about what happens when automated systems are granted excessive autonomy without adequate safeguards — and a model for the mechanisms that can prevent catastrophe.
Algorithmic trading systems execute transactions at speeds and volumes that no human trader could match. By 2024, algorithmic and high-frequency trading accounted for an estimated 60-70% of equity market volume in the United States. The efficiency gains are substantial, but the risks are systemic.
The 2010 "Flash Crash," in which the Dow Jones Industrial Average dropped nearly 1,000 points in minutes before recovering, demonstrated that autonomous trading algorithms could amplify market volatility beyond human reaction time. The response was not to ban algorithmic trading but to implement structural safeguards:
Circuit breakers. Market-wide circuit breakers (MWCBs) halt trading when price declines exceed predetermined thresholds — 7%, 13%, and 20% drops trigger progressive halts [4]. These are hard limits on autonomous system behavior, imposed externally and non-negotiable. The manufacturing equivalent would be hard-coded parameter boundaries that no AI agent can exceed, regardless of its model's output.
Regulatory oversight of algorithms. Financial regulators require that trading algorithms undergo pre-deployment testing, maintain audit trails of every decision, and operate within defined risk parameters. The Bank for International Settlements has emphasized that AI-driven financial systems require enhanced governance frameworks, including model risk management, third-party dependency controls, and mechanisms to address the correlation risks that emerge when multiple institutions use similar AI models [5].
Kill switches. Trading firms maintain the ability to immediately disable algorithmic systems. This is not a failure mode — it is a designed operational capability. The 2012 Knight Capital incident, in which a software deployment error caused the firm to lose $440 million in 45 minutes, reinforced the necessity of immediate human override capability.
The Financial Stability Board's 2024 report identifies AI-specific risks that translate directly to manufacturing contexts: third-party concentration risk (reliance on a small number of AI providers), model correlation risk (multiple systems trained on similar data making correlated errors), and the challenge of explainability in audit-critical environments [5].
The finance lesson is clear: speed and efficiency must be paired with structural safeguards that operate independently of the autonomous system itself. Trust is not a configuration parameter — it is an infrastructure requirement.
Cross-Industry Trust Architecture: A Comparative View
To synthesize the lessons from these three industries, we present a comparative analysis of how each domain structures its AI trust architecture.
| Dimension | Aviation | Medicine | Finance | Manufacturing (Current State) |
|---|---|---|---|---|
| AI autonomy level | High in routine operations; human authority retained for exceptions and emergencies | Advisory: AI provides recommendations, clinician decides | High-speed autonomous execution within hard-coded boundaries | Nascent: mostly Level 0–1, limited supervised execution |
| Primary control mechanism | Certification, redundancy, defined reversion to manual control | Regulatory approval (FDA), clinical validation, predetermined change control | Circuit breakers, position limits, real-time risk monitoring, kill switches | Varies widely; often ad hoc or inherited from general IT governance |
| Regulatory framework | FAA/EASA certification; DO-178C for software | FDA 21 CFR Part 820; SaMD guidance; EU MDR | SEC/CFTC oversight; MiFID II; BIS guidelines | EU AI Act (high-risk classification); ISO 9001/IATF 16949 for quality; limited AI-specific regulation |
| Liability model | Manufacturer (design), airline (operation), crew (execution) | Device manufacturer, clinician, institution | Firm bears trading losses; regulatory fines for compliance failures | Undefined for AI-specific decisions; general product liability applies |
| Trust maturity | Decades of data; millions of operational hours; mature feedback loops | Growing body of clinical evidence; FDA has authorized 1,000+ AI devices | Extensive market data; post-crisis regulatory refinement | Early stage; limited operational data; frameworks under development |
Table 1. Cross-industry comparison of AI trust architectures. Sources: SAE J3016 [2], FDA [3], BIS [5], EU AI Act [6].
Figure 1. Comparative radar chart of AI trust architecture maturity across four industries. Values (1–10 scale) are derived from the qualitative assessments in Table 1. Manufacturing's compact footprint highlights the gap in regulatory maturity, control mechanisms, and liability clarity compared to industries with decades of autonomous systems experience. Sources: SAE J3016 [2], FDA [3], BIS [5], EU AI Act [6].
This comparison reveals a consistent pattern: in every domain where AI autonomy has been successfully deployed, the trust framework was developed before — or, in the finance case, immediately after — the technology reached its operational limits. Manufacturing has the advantage of learning from all three.
An Author's Framework: Three Trust Zones for Manufacturing AI Agents
Based on our implementation experience across manufacturing verticals and the cross-industry analysis presented above, we propose a practical framework for defining AI agent trust boundaries in industrial settings. The framework defines three concentric trust zones, each with distinct authority levels, control mechanisms, and applicable use cases.
Zone 1: Recommendations Only (Outer Zone)
Authority: The AI agent analyzes data, identifies patterns, and presents recommendations. All decisions and actions remain with human operators. The agent has no ability to modify systems, trigger processes, or communicate externally without human mediation.
Control mechanisms: Read-only access to data systems. Output is informational only. No tool execution capability beyond data retrieval and analysis.
Applicable domains: Safety-critical decisions. Quality release/hold decisions. Regulatory submissions. Equipment shutdown/startup. Any decision where the cost of error is high and irreversible.
Industry precedent: Medical AI diagnostics (computer-aided detection). Aviation weather advisory systems.
Zone 2: Action with Confirmation (Middle Zone)
Authority: The AI agent proposes specific actions and prepares them for execution, but requires explicit human confirmation before any action is taken. The agent may have write access to staging environments or draft states, but not to production systems directly.
Control mechanisms: Human-in-the-loop approval for every consequential action. Audit trail of all proposals, including rejected ones. Time-limited approval windows — if a human does not confirm within a defined period, the proposal expires. Escalation paths for proposals that exceed defined parameters.
Applicable domains: Production scheduling adjustments. Maintenance work order generation. Inventory reorder proposals. Process parameter optimization suggestions. Deviation report drafting.
Industry precedent: Aviation autopilot engagement/disengagement protocols. Financial trading pre-trade risk checks. FDA predetermined change control plans.
Zone 3: Full Autonomy (Inner Core)
Authority: The AI agent executes tasks independently within strictly defined boundaries. Human oversight is periodic (shift-level or daily review), not per-action.
Control mechanisms: Hard-coded parameter boundaries that cannot be exceeded. Circuit breakers that halt autonomous operation when anomalies are detected. Comprehensive logging of every action with reasoning trace. Automatic reversion to Zone 2 (confirmation required) when the agent encounters conditions outside its training distribution. Regular human audit of agent decisions and outcomes.
Applicable domains: Routine data aggregation and reporting. Environmental monitoring within established ranges. Predictive maintenance alerts for non-critical equipment. Document classification and routing. Automated quality data collection and statistical process control charting.
Industry precedent: Autopilot cruise management in commercial aviation. Algorithmic execution of routine, low-risk financial transactions. Automated lab result processing in clinical settings.
The critical design principle is that zone assignment should be determined by the consequences of error, not by the capability of the system. An AI agent may be technically capable of autonomously adjusting critical process parameters with high accuracy. But if an error in that adjustment could cause a safety incident, a batch loss, or a regulatory violation, the domain belongs in Zone 1 regardless of the model's performance metrics.
The EU AI Act reinforces this consequence-based approach. Under Regulation (EU) 2024/1689, AI systems used in critical infrastructure — including manufacturing process control — are classified as high-risk and subject to requirements for risk management, human oversight, transparency, and accuracy [6]. The three-zone framework aligns with these requirements by ensuring that the highest-consequence decisions receive the most restrictive treatment.
NIST's AI Risk Management Framework provides additional structure, emphasizing that trustworthy AI systems must be valid and reliable, safe, secure, accountable, transparent, explainable, privacy-enhanced, and fair [7]. These characteristics map directly to the control mechanisms in each zone: transparency and explainability are minimum requirements even in Zone 3, while accountability and human oversight intensify as we move outward to Zone 1.
Anthropic's Responsible Scaling Policy offers a complementary perspective from the AI development side. Their framework establishes AI Safety Levels (ASLs) that scale safety and security requirements proportionally with increasing model capabilities [8]. The principle is identical: as capability increases, so must the rigor of safeguards. For manufacturing, this means that as AI agents become more capable — handling more complex tasks, integrating with more systems, operating with less supervision — the governance framework must evolve in lockstep.
Implementing Trust Boundaries: Practical Considerations
The framework above provides a conceptual structure, but implementation requires addressing several practical challenges that we consistently encounter in industrial deployments.
Zone assignment is not static. An AI agent may begin in Zone 1 for a given process, graduate to Zone 2 after demonstrating reliable performance over a defined period, and potentially reach Zone 3 for specific, well-bounded subtasks. The aviation model of earned autonomy applies directly: promotion between zones should require documented evidence of performance, not assumptions about capability.
Cross-zone operations require careful design. A single AI agent may operate in different zones for different tasks simultaneously. For example, an agent monitoring production quality might operate in Zone 3 for data collection and SPC charting (routine, low-risk), Zone 2 for suggesting parameter adjustments (consequential, reversible), and Zone 1 for recommending batch holds (high-impact, regulatory). The system architecture must enforce these boundaries at the tool-access level, not merely through policy.
Audit trails are non-negotiable. Across all three reference industries, one requirement is universal: every automated decision must be traceable. The agent's reasoning, the data it relied upon, the alternatives it considered, and the authority under which it acted must all be recorded. In our experience, organizations that invest in comprehensive logging from the outset avoid costly retrofitting when regulatory or quality audits require decision traceability.
Organizational culture shapes trust more than technology. In our observations across dozens of industrial deployments, the most technically sophisticated AI agent will fail if the organization lacks a culture of data-driven decision-making, clear accountability structures, and willingness to adapt workflows. Conversely, organizations with mature process discipline can extract significant value even from relatively simple AI agent implementations — because they know how to define boundaries, monitor compliance, and learn from operational data.
Author's Assessment and Conclusions
The question of how much to trust an AI agent is, at its core, the same question that aviation, medicine, and finance have each answered through decades of practice: how do you grant autonomy to a system that is powerful but imperfect, in environments where errors have real consequences?
Based on our experience implementing AI in manufacturing environments and the cross-industry analysis presented in this article, we offer the following assessment:
First, manufacturing should not invent its trust framework from scratch. Aviation's graduated autonomy model, medicine's advisory-first approach, and finance's structural safeguard architecture provide proven templates. The three-zone framework we propose synthesizes these precedents into a manufacturing-applicable structure.
Second, trust boundaries must be defined by consequences, not capabilities. The temptation to expand AI autonomy because the technology is capable is precisely the error that the 2010 Flash Crash and numerous aviation incidents have demonstrated. In our practice, we consistently advocate for conservative initial zone assignments with evidence-based promotion — an approach that may slow initial deployment but dramatically reduces the risk of trust-destroying failures.
Third, the EU AI Act and NIST AI RMF provide regulatory anchors that manufacturing enterprises should adopt proactively, not reactively. Organizations that build AI governance frameworks aligned with these standards today will have a structural advantage as regulatory requirements intensify — and they will build the operational discipline that makes higher-autonomy AI deployments viable in the future.
Fourth, the most overlooked element of AI trust is organizational readiness. Technology vendors tend to focus on model accuracy and capability benchmarks. But in our observation, the enterprises that successfully deploy AI agents at Zone 2 and above are those that have invested equally in process documentation, data governance, staff training, and clear accountability structures. The trust boundary for an AI agent is ultimately defined not by the technology but by the maturity of the organization that deploys it.
The path forward for manufacturing is not to resist AI autonomy but to govern it — with the same rigor, humility, and systematic approach that aviation, medicine, and finance have demonstrated. The lessons are available. The frameworks exist. The remaining variable is organizational will.
References
- McKinsey & Company. "From Pilots to Performance: How COOs Can Scale AI in Manufacturing." 2025. https://www.mckinsey.com/capabilities/operations/our-insights/from-pilots-to-performance-how-coos-can-scale-ai-in-manufacturing
- SAE International. "J3016: Taxonomy and Definitions for Terms Related to Driving Automation Systems for On-Road Motor Vehicles." 2021. https://www.sae.org/standards/content/j3016_202104/
- FDA. "Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations." 2025. https://www.fda.gov/news-events/press-announcements/fda-issues-comprehensive-draft-guidance-developers-artificial-intelligence-enabled-medical-devices
- SEC / NYSE. "Market-Wide Circuit Breakers." 2022. https://www.nyse.com/markets/nyse/market-wide-circuit-breakers
- Bank for International Settlements. "Financial Stability Implications of Artificial Intelligence." 2024. https://www.bis.org/fsi/fsisummaries/exsum_23904.htm
- European Parliament and Council. "Regulation (EU) 2024/1689 — The EU AI Act." 2024. https://op.europa.eu/en/publication-detail/-/publication/d79f3e5d-41bc-11f0-b9f2-01aa75ed71a1/language-en
- NIST. "AI Risk Management Framework (AI RMF 1.0)." 2023. https://www.nist.gov/itl/AI-risk-management-framework
- Anthropic. "Responsible Scaling Policy v3.0." 2026. https://anthropic.com/responsible-scaling-policy/rsp-v3-0